Physician profile
Benjamin Golas
NPI 1619011657
$18,100.30
in general payments reported to CMS, 2019-2025
17 companies · $354 in 2025
The $354 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,064 · 2020: $51.73 · 2021: $6,636 · 2022: $8,028 · 2023: $489 · 2024: $478 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,320.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $11,088.59 | 2021-2022 | |
| Intuitive Surgical, INC. | $3,535.48 | 2019-2024 | |
| Ethicon US, LLC | $2,438.22 | 2021-2024 | Neuwave, Echelon Endopath, Enseal |
| Innocoll Pharmaceuticals Limited | $324.91 | 2023 | Xaracoll |
| Davol INC. | $155.30 | 2025 | Surgiphor |
| Medtronic, INC. | $152.28 | 2024-2025 | Endoflip, Signia |
| Ambu INC. | $117.88 | 2023 | |
| Dilon Technologies, INC. | $48.75 | 2024 | Hemoblast Bellows |
| Becton, Dickinson and Company | $40.36 | 2024 | Phasix Mesh |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $39.25 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $35.28 | 2024 | Tagrisso |
| Kerecis Limited | $28.55 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Abbvie INC. | $28.37 | 2024 | |
| Organogenesis INC. | $18.89 | 2023 | Puraply |
| Avadel Cns Pharmaceuticals, LLC | $16.83 | 2025 | Lumryz |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solventum Corporation | $16.07 | 2024 | Prevena, V.A.C. Veraflo, V.A.C.Ulta |
| Integra Lifesciences Corporation | $15.29 | 2025 | Integra, Surgimend, Integra Dermal Regeneration Template |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Golas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.